Heading Into Earnings, Expectations Are Rising For These 4 Biotech Stocks
Heading into an earnings season in which many companies will be posting much lower earnings as a result of the pandemic.
Heading into an earnings season in which many companies will be posting much lower earnings as a result of the pandemic.
Three biotech companies developing therapies for the treatment of cancer and other diseases – including infectious diseases like COVID-19 – began trading on Friday.
A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts.
A look at the four biotech companies going public Friday – which include two firms developing small molecule therapies to treat cancer.
“Make no mistake: These stocks are risky. Nonetheless, each of these companies has a few factors in its favor aside from being popular with retail traders, so if you’re looking for a high-risk and high-reward stock to add to your portfolio, one of these might be worth buying,”
Which biotech stocks will be the next to reward risk-tolerant investors with massive returns?
“The health care sector, some biotech stocks in particular, are looking to explode in 2021,” declares the author of today’s article, who further notes that “There have been some breakout companies as a result of the coronavirus pandemic, but other catalysts will be playing into the expected gains as well.”
The four penny stocks highlighted in today’s article are all biopharmaceutical/biotech companies, they can all be bought for under $4, and they all have important upcoming events.
“September has historically been the worst-performing month for stocks – and today’s article identifies the stocks that have shown themselves to be the worst stocks to own in September over the past 10 years.
“Be it COVID vaccine or cancer research, small-cap biotech companies are making their presence felt in every area,”